Latest On Entera Bio Ltd (ENTX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-08 23:22 EST | News | Amgen, Entera end research collaboration | N/A |  |
| 2023-05-06 02:18 EST | News | Entera Bio GAAP EPS of -$0.08 beats by $0.04 | N/A | |
| 2023-04-03 02:15 EST | News | Entera Bio GAAP EPS of -$0.45 | N/A | |
| 2023-03-23 18:28 EST | News | Entera Bio regains Nasdaq listing requirements compliance | N/A | |
| 2023-02-15 23:54 EST | News | Entera Bio up 9% after FDA agrees to review design for phase 3 osteoporosis candidate | N/A | |
| 2022-11-11 09:19 EST | News | Entera Bio GAAP EPS of -$0.11 | N/A | |
| 2022-10-06 10:55 EST | News | FDA agrees to single phase 3 trial by Entera for bone disorder drug EB613 to support approval | N/A | |
| 2022-08-12 01:51 EST | News | Entera Bio GAAP EPS of -$0.24 , revenue of $0.11M | N/A | |
| 2022-07-18 11:15 EST | News | Entera stock rises 13% amid CFO taking charge as CEO, getting FDA meeting for lead drug | N/A | |
| 2022-05-19 01:58 EST | News | Entera Bio Ltd. (ENTX) CEO Spiros Jamas on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-16 11:28 EST | News | Entera Bio names Miranda Toledano as CBO, CFO | N/A | |
| 2022-05-12 16:48 EST | News | Entera Bio GAAP EPS of -$0.13 beats by $0.05, revenue of $0.07M misses by $0.02M | N/A | |
| 2022-04-02 16:07 EST | News | Entera Bio (ENTX) Investor Presentation - Slideshow | N/A | |
| 2022-03-08 12:53 EST | News | Entera Bio GAAP EPS of -$0.47 beats by $0.58, revenue of $0.57M beats by $0.03M | N/A | |
| 2022-03-08 12:52 EST | News | Entera Bio's (ENTX) CEO Spiros Jamas on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-01-04 12:20 EST | News | Entera Bio completes End-of-Phase 2 meeting with FDA on osteoporosis drug | N/A | |
| 2021-11-11 05:16 EST | News | Entera Bio reports 9M results | N/A | |
| 2021-10-07 09:32 EST | News | Entera Bio releases positive mid-stage data on osteoporosis candidate | N/A | |
| 2021-08-16 17:08 EST | News | Entera Bio EPS misses by $0.51, beats on revenue | N/A | |
| 2021-08-16 17:07 EST | News | Entera Bio Ltd. (ENTX) CEO Spiros Jamas on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-21 06:42 EST | News | Entera Bio secures European patent for oral PTH formulations | N/A | |
| 2021-07-21 06:35 EST | News | Entera Bio shares surge on mid-stage osteoporosis study data | N/A | |
| 2021-04-15 19:02 EST | News | Entera appoints Ramesh Ratan as CFO | N/A | |
| 2021-04-14 07:03 EST | News | Our First Look At Entera Bio | N/A | |
| 2021-03-18 18:07 EST | News | Entera Bio EPS beats by $0.01, beats on revenue | N/A | |
| 2021-03-18 18:07 EST | News | Entera Bio's (ENTX) CEO Spiros Jamas on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-03-12 23:57 EST | News | Entera Bio continues surge following osteoporosis drug results; up 52% premarket | N/A | |
| 2021-03-12 11:33 EST | Analyst Rating | The Analyst Target Price has increased from $5 to $10. | Buy | |
| 2021-03-12 03:04 EST | News | Entera Bio shares soar on mid-stage osteoporosis treatment data | N/A | |
| 2021-01-28 07:34 EST | Analyst Rating | The Analyst Target Price has increased from $4 to $5. | Buy | |
| 2020-12-10 11:18 EST | News | Entera Bio soars 25% after FDA gives green light to EB613 application in osteoporosis | N/A | |
| 2020-11-26 19:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-25 11:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-24 07:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-19 16:43 EST | News | Entera Bio EPS misses by $0.22 | N/A | |
| 2020-11-19 16:42 EST | News | Entera Bio Ltd. (ENTX) CEO Roger Garceau on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-11-10 12:34 EST | News | Entera Bio completes enrollment in Phase 2 trial of EB613 in Osteoporosis | N/A | |
| 2020-11-07 15:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 12:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 04:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-04 20:38 EST | Analyst Rating | The Analyst Target Price has decreased from $8 to $4. | Neutral | |
| 2020-08-25 08:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-25 06:56 EST | News | Entera Osteoporosis Trial, And Other News: The Good, Bad And Ugly Of Biopharma | N/A | |
| 2020-08-22 08:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-21 04:36 EST | Earnings Estimate | An EPS average of -$0.68 is estimated for the 2021 year. | Sell | |
| 2020-08-21 04:36 EST | Earnings Estimate | An EPS average of -$0.13 is estimated for the quarter ending on September 30, 2020. | Buy | |
| 2020-08-20 16:43 EST | News | Entera Bio EPS misses by $0.01, beats on revenue | N/A | |
| 2020-08-20 16:43 EST | News | Entera Bio up 7% on encouraging data on osteoporosis candidate | N/A | |
| 2020-08-20 16:41 EST | News | Entera Bio Ltd. (ENTX) Interim CEO Roger Garceau on Q2 2020 Results - Earnings Call Transcript | N/A | |
| 2020-08-14 08:42 EST | Financials | Company financials have been released. | Neutral | |
About Entera Bio Ltd (ENTX):
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase II clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. The company was founded in 2009 and is based in Jerusalem, Israel.
General
- Name Entera Bio Ltd
- Symbol ENTX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 19
- Fiscal Year EndDecember
- IPO Date2018-06-28
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.enterabio.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 476.47
- Price/Book (Most Recent Quarter) 20.11
- Enterprise Value Revenue 552.16
View More
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.15
- Operating Margin -5141%
- Return on Assets -98%
- Return on Equity -229%
- Revenue 246000
- Earnings Per Share -$1.05
- Revenue Per Share $0.01
- Gross Profit 26000
- Quarterly Earnings Growth -16.7%
View More
Highlights
- Market Capitalization 102.16 million
- EBITDA -10381000
- Analyst Target Price $10
- Book Value Per Share $0.31
View More
Share Statistics
- Shares Outstanding 21.06 million
- Shares Float 10.57 million
- % Held by Insiders 4120%
- % Held by Institutions 10.38%
- Shares Short 135526
- Shares Short Prior Month 156528
- Short Ratio 0.23
- Short % of Float 1%
- Short % of Shares Outstanding 1%
View More
Technicals
- Beta 1.34
- 52 Week High $6.47
- 52 Week Low $1
- 50 Day Moving Average 2.24
- 200 Day Moving Average 1.44
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Entera Bio Ltd (ENTX) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Entera Bio Ltd (ENTX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-19 | $50000 | -$0.09 | -$0.20 | 55% |
| 2020-06-30 | 2020-08-20 | $N/A | -$0.17 | -$0.12 | -41.67% |
| 2020-03-31 | 2020-05-21 | $42000 | -$0.16 | ||
| 2019-12-31 | 2020-03-26 | $N/A | -$0.26 | -$0.19 | -36.84% |
| 2019-09-30 | 2019-11-21 | $60000 | -$0.25 | -$0.15 | -66.67% |
| 2019-06-30 | 2019-08-20 | $74000 | -$0.12 | -$0.28 | 57.14% |
| 2019-03-31 | 2019-06-27 | $N/A | -$0.26 | ||
| 2018-12-31 | 2019-03-28 | $500000 | -$0.17 | -$0.35 | 51.43% |
| 2018-09-30 | 2018-09-30 | $N/A | -$0.45 | -$0.28 | -60.71% |
| 2018-06-30 | 2018-08-20 | $N/A | -$0.93 | -$0.08 | -1062.5% |
| 2018-03-31 | 2018-06-29 | $N/A | -$13.97 | -$0.08 | -17362.5% |
Entera Bio Ltd (ENTX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Entera Bio Ltd (ENTX) Chart:
Entera Bio Ltd (ENTX) News:
Below you will find a list of latest news for Entera Bio Ltd (ENTX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Entera Bio Ltd (ENTX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0.25 | CALL | 1 | 285 | 140.45 | FALSE | -0.1 | -0.29 |
| 2024-05-17 | 5 | 0.15 | CALL | 1 | 172 | 255.01 | FALSE | 0.1 | 2 |
| 2024-05-17 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 0.6 | PUT | 10 | 14 | 172.43 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 2.5 | PUT | 0 | 1 | 525.25 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 504.16 | TRUE | 0 | 0 |
| 2024-08-16 | 2.5 | 1.55 | CALL | 0 | 1051 | 131.52 | FALSE | 0 | 0 |
| 2024-08-16 | 5 | 0.58 | CALL | 0 | 17 | 164.45 | FALSE | 0 | 0 |
| 2024-08-16 | 7.5 | 0.9 | CALL | 0 | 9 | 165.61 | FALSE | 0 | 0 |
| 2024-08-16 | 2.5 | 0.86 | PUT | 0 | 2 | 164.25 | TRUE | 0 | 0 |
| 2024-08-16 | 5 | 2.86 | PUT | 0 | 1 | 176.69 | TRUE | 0 | 0 |
| 2024-08-16 | 7.5 | 0 | PUT | 0 | 0 | 289.54 | TRUE | 0 | 0 |
| 2024-11-15 | 2.5 | 1.5 | CALL | 0 | 25 | 149.55 | FALSE | 0 | 0 |
| 2024-11-15 | 5 | 0.7 | CALL | 0 | 35 | 142.32 | FALSE | 0 | 0 |
| 2024-11-15 | 7.5 | 0.4 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 2.5 | 1 | PUT | 0 | 1 | 138.85 | TRUE | 0 | 0 |
| 2024-11-15 | 5 | 0 | PUT | 0 | 0 | 169.14 | TRUE | 0 | 0 |
| 2024-11-15 | 7.5 | 0 | PUT | 0 | 0 | 156 | TRUE | 0 | 0 |
Latest ENTX Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 6:56 PM EST | 9 | $1.69 |
| Jun 13, 2022 7:04 PM EST | 200 | $1.7 |
| Jun 13, 2022 7:59 PM EST | 10 | $1.67 |
| Jun 13, 2022 7:59 PM EST | 1 | $1.67 |
| Jun 13, 2022 7:59 PM EST | 2 | $1.67 |
Entera Bio Ltd (ENTX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891320001873/0001178913-20-001873-index.htm |
| 2015-05-01 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1638097/000000000015024186/0000000000-15-024186-index.htm |
| 2017-08-11 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1638097/000000000017028456/0000000000-17-028456-index.htm |
| 2017-10-05 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1638097/000000000017035393/0000000000-17-035393-index.htm |
| 2017-11-17 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1638097/000000000017040784/0000000000-17-040784-index.htm |
| 2018-06-12 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1638097/000000000018017987/0000000000-18-017987-index.htm |
| 2018-06-22 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1638097/000000000018019310/0000000000-18-019310-index.htm |
| 2018-06-26 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1638097/000000000018019609/0000000000-18-019609-index.htm |
| 2020-06-11 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1638097/000000000020005210/0000000000-20-005210-index.htm |
| 2020-07-17 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1638097/000000000020006561/0000000000-20-006561-index.htm |
| 2015-05-18 | DRSLTR | Correspondence Related to Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1638097/000095010315003978/0000950103-15-003978-index.htm |
| 2017-07-14 | DRS | Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1638097/000095010317006747/0000950103-17-006747-index.htm |
| 2017-09-20 | DRS/A | Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1638097/000095010317009050/0000950103-17-009050-index.htm |
| 2017-09-20 | DRSLTR | Correspondence Related to Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1638097/000095010317009051/0000950103-17-009051-index.htm |
| 2017-10-19 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1638097/000095010317010087/0000950103-17-010087-index.htm |
| 2017-11-03 | DRS/A | Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1638097/000095010317010810/0000950103-17-010810-index.htm |
| 2017-11-03 | DRSLTR | Correspondence Related to Draft Registration Statement | https://www.sec.gov/Archives/edgar/data/1638097/000095010317010811/0000950103-17-010811-index.htm |
| 2017-11-09 | F-1 | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1638097/000095010317011026/0000950103-17-011026-index.htm |
| 2017-11-17 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1638097/000095010317011326/0000950103-17-011326-index.htm |
| 2017-11-20 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1638097/000095010317011366/0000950103-17-011366-index.htm |
| 2017-11-20 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1638097/000095010317011367/0000950103-17-011367-index.htm |
| 2018-01-19 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1638097/000095010318000611/0000950103-18-000611-index.htm |
| 2018-01-19 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1638097/000095010318000612/0000950103-18-000612-index.htm |
| 2018-01-29 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1638097/000095010318000930/0000950103-18-000930-index.htm |
| 2018-01-29 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1638097/000095010318000931/0000950103-18-000931-index.htm |
| 2018-05-17 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1638097/000095010318006271/0000950103-18-006271-index.htm |
| 2018-06-25 | 8-A12B | Registration of securities [Section 12(b)] | https://www.sec.gov/Archives/edgar/data/1638097/000095010318007696/0000950103-18-007696-index.htm |
| 2018-06-25 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1638097/000095010318007723/0000950103-18-007723-index.htm |
| 2018-06-25 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1638097/000095010318007724/0000950103-18-007724-index.htm |
| 2018-09-24 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1638097/000095010318010965/0000950103-18-010965-index.htm |
| 2019-02-08 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1638097/000095010319001835/0000950103-19-001835-index.htm |
| 2019-04-17 | 20-F/A | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1638097/000095010319004878/0000950103-19-004878-index.htm |
| 2019-12-26 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1638097/000095010319017690/0000950103-19-017690-index.htm |
| 2020-02-27 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1638097/000095010320003564/0000950103-20-003564-index.htm |
| 2020-06-22 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1638097/000095010320012104/0000950103-20-012104-index.htm |
| 2020-08-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000095010320015494/0000950103-20-015494-index.htm |
| 2020-06-05 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1638097/000110465920070434/0001104659-20-070434-index.htm |
| 2020-07-13 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1638097/000110465920083148/0001104659-20-083148-index.htm |
| 2020-07-20 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1638097/000110465920084761/0001104659-20-084761-index.htm |
| 2018-01-05 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1638097/000114420418000927/0001144204-18-000927-index.htm |
| 2018-06-15 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1638097/000114420418034345/0001144204-18-034345-index.htm |
| 2018-06-15 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1638097/000114420418034349/0001144204-18-034349-index.htm |
| 2018-06-25 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1638097/000114420418035496/0001144204-18-035496-index.htm |
| 2018-06-25 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1638097/000114420418035497/0001144204-18-035497-index.htm |
| 2018-06-27 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1638097/000114420418035925/0001144204-18-035925-index.htm |
| 2018-06-26 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1638097/000114420418035926/0001144204-18-035926-index.htm |
| 2018-06-29 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1638097/000114420418036705/0001144204-18-036705-index.htm |
| 2018-08-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891318002361/0001178913-18-002361-index.htm |
| 2018-08-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891318002426/0001178913-18-002426-index.htm |
| 2018-08-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891318002438/0001178913-18-002438-index.htm |
| 2018-09-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891318002565/0001178913-18-002565-index.htm |
| 2018-09-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891318002587/0001178913-18-002587-index.htm |
| 2018-10-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891318002607/0001178913-18-002607-index.htm |
| 2018-11-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891318002858/0001178913-18-002858-index.htm |
| 2018-12-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891318003123/0001178913-18-003123-index.htm |
| 2019-01-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319000082/0001178913-19-000082-index.htm |
| 2019-01-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319000125/0001178913-19-000125-index.htm |
| 2019-01-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319000217/0001178913-19-000217-index.htm |
| 2019-02-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1638097/000117891319000429/0001178913-19-000429-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1638097/000117891319000484/0001178913-19-000484-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1638097/000117891319000492/0001178913-19-000492-index.htm |
| 2019-03-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319000761/0001178913-19-000761-index.htm |
| 2019-03-28 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319000961/0001178913-19-000961-index.htm |
| 2019-03-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319000964/0001178913-19-000964-index.htm |
| 2019-04-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319001132/0001178913-19-001132-index.htm |
| 2019-05-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319001579/0001178913-19-001579-index.htm |
| 2019-06-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319001773/0001178913-19-001773-index.htm |
| 2019-07-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319001805/0001178913-19-001805-index.htm |
| 2019-08-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319002037/0001178913-19-002037-index.htm |
| 2019-08-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319002223/0001178913-19-002223-index.htm |
| 2019-08-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319002284/0001178913-19-002284-index.htm |
| 2019-09-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319002384/0001178913-19-002384-index.htm |
| 2019-10-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319002476/0001178913-19-002476-index.htm |
| 2019-11-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319002805/0001178913-19-002805-index.htm |
| 2019-11-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319002807/0001178913-19-002807-index.htm |
| 2019-12-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319002914/0001178913-19-002914-index.htm |
| 2019-12-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891319002944/0001178913-19-002944-index.htm |
| 2020-01-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891320000104/0001178913-20-000104-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1638097/000117891320000440/0001178913-20-000440-index.htm |
| 2020-02-18 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1638097/000117891320000506/0001178913-20-000506-index.htm |
| 2020-02-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891320000593/0001178913-20-000593-index.htm |
| 2020-03-09 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1638097/000117891320000755/0001178913-20-000755-index.htm |
| 2020-03-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891320000929/0001178913-20-000929-index.htm |
| 2020-03-26 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1638097/000117891320000939/0001178913-20-000939-index.htm |
| 2020-05-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891320001448/0001178913-20-001448-index.htm |
| 2020-05-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891320001557/0001178913-20-001557-index.htm |
| 2020-05-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891320001565/0001178913-20-001565-index.htm |
| 2020-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891320001873/0001178913-20-001873-index.htm |
| 2020-07-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891320001972/0001178913-20-001972-index.htm |
| 2020-07-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891320002075/0001178913-20-002075-index.htm |
| 2020-08-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891320002255/0001178913-20-002255-index.htm |
| 2020-08-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891320002446/0001178913-20-002446-index.htm |
| 2020-08-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891320002470/0001178913-20-002470-index.htm |
| 2020-08-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1638097/000117891320002472/0001178913-20-002472-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1638097/000121390019002450/0001213900-19-002450-index.htm |
| 2020-01-21 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1638097/000121390020001454/0001213900-20-001454-index.htm |
| 2019-04-10 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1638097/000121465919002672/0001214659-19-002672-index.htm |
| 2020-03-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1638097/000121465920002526/0001214659-20-002526-index.htm |
| 2018-06-26 | CERT | Certification | https://www.sec.gov/Archives/edgar/data/1638097/000135445718000237/0001354457-18-000237-index.htm |
| 2018-01-11 | F-1/A | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1638097/000157104918000023/0001571049-18-000023-index.htm |
| 2018-06-27 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1638097/999999999518001631/9999999995-18-001631-index.htm |
| 2020-06-24 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1638097/999999999520001525/9999999995-20-001525-index.htm |
| 2020-07-22 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1638097/999999999520001890/9999999995-20-001890-index.htm |